Recombinant Human MDM4 Protein: Research Guide & Applications

Recombinant Human MDM4 Protein is a critical research reagent for investigating the negative regulation of the p53 tumor suppressor pathway, enabling studies of protein–protein interactions, drug target validation, and cancer biology mechanisms.

Product Name

Recombinant Human MDM4 Protein

SKU

rp371774

Also Known As

MDMX, HDMX, MDM4

Protein Function

Negative regulator of p53 tumor suppressor; lacks intrinsic E3 ubiquitin ligase activity but inhibits p53 transcriptional activity

Key Application

p53–MDM4 interaction studies, drug screening, biochemical assays

Recommended Storage

-80°C for long-term storage; avoid repeated freeze-thaw cycles

Supplier Reference

absea#PP-5886

Biological Background of MDM4

MDM4 (also called MDMX or HDMX) is a member of the MDM family of proteins and a critical negative regulator of the p53 tumor suppressor. Unlike its paralog MDM2, MDM4 does not possess functional intrinsic E3 ubiquitin ligase activity but exerts its oncogenic effect primarily by directly binding to the p53 transactivation domain and suppressing p53-dependent transcription.

MDM4 is frequently overexpressed in human cancers that retain wild-type p53, including melanoma, retinoblastoma, and certain breast and colorectal cancers. Because MDM4 inhibits p53 through a mechanism distinct from MDM2-mediated proteasomal degradation, it represents an independent and clinically relevant cancer target. MDM4 also forms a stable heterodimer with MDM2 via their RING domains, which influences MDM2 E3 ligase activity and further modulates p53 stability and function.

Recombinant Human MDM4 Protein enables researchers to dissect these regulatory interactions in controlled biochemical and cell-free systems, supporting target validation, interaction mapping, and inhibitor screening campaigns.

Biochemical Properties and Protein Structure

Human MDM4 is encoded by the MDM4 gene located on chromosome 1q32. The full-length protein comprises approximately 490 amino acids and contains several functional domains: an N-terminal p53-binding domain (PBD) that mediates interaction with the p53 transactivation domain; a central acidic domain; a zinc finger domain; and a C-terminal RING domain responsible for MDM2 heterodimerization.

Recombinant Human MDM4 Protein produced for research use is typically expressed in a suitable heterologous expression system (such as E. coli or baculovirus/insect cell systems) and purified to high homogeneity. The recombinant form retains the structural integrity required for binding assays with p53 peptides or full-length p53 protein, making it suitable for surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), co-immunoprecipitation validation, and enzyme-linked immunosorbent assay (ELISA)-based interaction studies.

Note: Specific purity grade, expression host, tag configuration, and molecular weight for SKU rp371774 should be confirmed in the official product datasheet. Contact Aladdin Scientific technical support for the most current certificate of analysis.

Recommended Handling, Reconstitution, and Storage Protocol

Proper handling of Recombinant Human MDM4 Protein is essential to maintain biological activity and ensure reproducible experimental results. Follow the guidelines below:

• Receipt: Upon receipt, briefly centrifuge the vial to collect contents at the bottom. Inspect for visible particulates or discoloration before use.
• Reconstitution: If supplied lyophilized, reconstitute in the buffer recommended in the product datasheet (typically sterile PBS or Tris-based buffer with a carrier protein such as 0.1% BSA). Allow the vial to equilibrate at room temperature for 10–15 minutes before gently pipetting to dissolve. Do not vortex.
• Aliquoting: Prepare single-use aliquots immediately after reconstitution to minimize freeze-thaw degradation. Use low-binding microcentrifuge tubes to reduce protein adsorption losses.
• Storage: Store long-term at −80°C. For short-term use within 1–2 weeks, storage at 4°C may be acceptable if a stabilizing buffer with carrier protein is used. Avoid repeated freeze-thaw cycles, which can lead to aggregation and loss of binding activity.
• Working Concentration: Determine empirically for each assay format. Refer to published literature on MDM4–p53 interaction assays as a starting point.

Always consult the product-specific datasheet provided with SKU rp371774 for authoritative reconstitution volumes, buffer compositions, and stability data.

Research Applications

Recombinant Human MDM4 Protein supports a broad range of research applications in cancer biology, structural biology, and drug discovery:

• Protein–Protein Interaction Studies: MDM4 is widely used as a binding partner in assays characterizing the MDM4–p53 interaction interface, including SPR, ITC, fluorescence polarization (FP), and AlphaScreen/HTRF proximity assays.
• Inhibitor and Drug Screening: As a validated cancer target, MDM4 recombinant protein is used in high-throughput screening (HTS) campaigns to identify small molecules or peptides capable of disrupting the MDM4–p53 interaction, thereby restoring p53 tumor suppressor function.
• Structural Studies: High-purity recombinant MDM4 supports X-ray crystallography and cryo-electron microscopy (cryo-EM) studies aimed at resolving MDM4 domain structures and their complexes with p53 or inhibitory compounds.
• Antibody Validation: Recombinant MDM4 serves as a positive control antigen for validating anti-MDM4 antibodies in ELISA, western blot, and immunoprecipitation experiments.
• Cell-Free Transcription/Translation Assays: MDM4 protein can be incorporated into cell-free systems to study its suppressive effect on p53-driven transcription without confounding cellular variables.
• Biomarker Research: Used to develop and validate quantitative assays for MDM4 protein levels in clinical or preclinical cancer specimens.

Quality Considerations and Troubleshooting

To obtain reliable and reproducible data with Recombinant Human MDM4 Protein, consider the following quality and troubleshooting guidance:

• Activity Verification: Before initiating critical experiments, verify protein activity using a validated binding assay (e.g., ELISA or FP assay with a known p53 peptide). This confirms that the lot retains expected functional properties.
• Aggregation: If turbidity or precipitation is observed after reconstitution or thawing, centrifuge at 10,000–14,000 × g for 10 minutes at 4°C and use the clarified supernatant. Aggregated protein may yield false results in binding assays.
• Nonspecific Binding: Include appropriate negative controls (e.g., buffer-only wells, irrelevant recombinant protein) in all interaction assays to distinguish specific MDM4-mediated binding from background.
• Buffer Compatibility: Ensure that assay buffers are compatible with the protein storage buffer. Significant dilution into incompatible buffers (e.g., high-detergent or extreme-pH conditions) may denature the protein.
• Lot-to-Lot Variability: When transitioning between protein lots, perform a side-by-side comparison to confirm comparable activity. Request a certificate of analysis (CoA) for each lot from Aladdin Scientific.
• Endotoxin Levels: For cell-based assays, verify that endotoxin levels are within acceptable limits (typically <1 EU/μg) to avoid confounding inflammatory responses. Check the CoA or contact technical support.

Frequently asked questions

What is the difference between MDM4 and MDM2, and why does it matter for my experiment?

MDM2 and MDM4 are structural paralogs that both bind and suppress p53, but they act through distinct mechanisms. MDM2 is a functional E3 ubiquitin ligase that promotes p53 degradation via the proteasome, whereas MDM4 lacks this intrinsic ligase activity and instead directly inhibits p53 transcriptional activation. For drug discovery experiments, this distinction is critical: inhibitors targeting the MDM2–p53 interaction may not block MDM4–p53 binding, so both proteins may need to be included in screening panels to identify dual or selective inhibitors.

How should I validate that the Recombinant Human MDM4 Protein is active after reconstitution?

The most direct validation approach is a binding assay using a known MDM4-binding p53 peptide (e.g., derived from the p53 transactivation domain) in a format such as ELISA, fluorescence polarization, or bead-based proximity assay. Active MDM4 protein should demonstrate concentration-dependent, saturable binding to the p53 peptide. Including a positive control from a previously validated lot and a negative control (scrambled peptide or unrelated protein) will confirm assay integrity.

What cancer types are most relevant for MDM4 research?

MDM4 overexpression has been documented in several cancer types that retain wild-type p53, most notably cutaneous melanoma, retinoblastoma, acute lymphoblastic leukemia, and subsets of breast and colorectal cancers. Because MDM4 amplification or overexpression in these tumors effectively inactivates p53 without mutation, it is a compelling therapeutic target. Researchers studying these cancer models are primary users of Recombinant Human MDM4 Protein for mechanistic and drug-screening studies.

Can Recombinant Human MDM4 Protein be used for in vivo animal studies?

Recombinant human proteins are primarily intended for in vitro biochemical and cell-based research applications. Direct administration of recombinant human MDM4 protein in animal models is not a standard application due to immunogenicity concerns and the complexity of protein delivery in vivo. For in vivo studies of MDM4 function, researchers typically employ genetic approaches such as transgenic overexpression models, conditional knockout systems, or viral vector-mediated delivery. Consult your institutional guidelines and the product datasheet before any in vivo use.

How do I minimize protein loss due to adsorption to tube surfaces?

Use low-binding microcentrifuge tubes (e.g., siliconized or protein low-bind polypropylene tubes) for all dilutions and storage of Recombinant Human MDM4 Protein. Adding a carrier protein such as 0.1% BSA (bovine serum albumin) to the working buffer can also significantly reduce nonspecific surface adsorption. Avoid glass surfaces unless they have been treated to reduce protein binding.

References

1. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26(15):3453–3459.
2. Marine JC, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. J Cell Sci. 2007;120(3):371–378.
3. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13(2):83–96.
4. Shadfan M, Lopez-Pajares V, Yuan ZM. MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res. 2012;1(2):88–89.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.